NYSE: ARXAccelerant Holdings Stock
$29.79+3.29 (+12.42%)
Updated Jul 25, 2025
ARX Price
$29.79
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$25.94
52 Week High
$31.18
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
19.48
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ARX's potential to beat the market
- ARX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Insurance
Industry Rating
C
ARX
RankedUnranked of 15
RankedUnranked of 15
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.60 | A | |
| $88.74 | B | |
| $2.00 | C |
Be the first to know about important ARX news, forecast changes, insider trades & much more!
ARX News
Overview
Due Diligence Score
–
Industry Average (35)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ARX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARX's debt to equity ratio (19.48) is considered high
Healthy Debt to Equity Financials
Insufficient data to perform Discounted Cash Flow valuation for ARX
Below Fair Value Valuation
Insufficient data to perform Discounted... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
There are 30 more ARX due diligence checks available for Premium users.
Valuation
ARX's financial health
Profit margin
Revenue
$178.0M
Net Income
$6.5M
Profit Margin
3.7%
Assets to liabilities
Assets
$6.7B
Liabilities
$6.3B
Debt to equity
19.48
ARX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$91.8M
Investing
-$89.7M
Financing
-$2.3M
ARX vs Insurance Stocks
Accelerant Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.